Pipeline / BPC-203

oncology · biologic

BPC-203 — Relapsed/refractory B-cell lymphoma

A humanized monoclonal antibody targeting CD19 with an engineered Fc region for enhanced antibody-dependent cellular cytotoxicity. Phase 1 is enrolling patients with relapsed or refractory B-cell lymphoma.

phase 1 Target: Cluster of differentiation 19 (CD19) Sample data

Investigational candidate. BPC-203 has not been approved by any regulatory authority.

Mechanism of action

How the molecule works.

BPC-203 binds CD19 on the surface of B cells and recruits natural killer cells through its engineered Fc, driving selective depletion of malignant B cells.

Milestones

Program timeline.

  1. 2022 Lead selected done
  2. 2023 IND clearance done
  3. 2024 Phase 1 first-patient-in done
  4. 2025 Dose escalation ongoing current
  5. 2026 Recommended Phase 2 dose planned

Clinical trials

1 trial for BPC-203.

NCT-BPC203-101

Phase 1 first-in-human study of BPC-203 in B-cell lymphoma

Recruiting phase 1 32/60 enrolled

Publications

3 related publications.

  • mAbs 2024

    An Fc-engineered anti-CD19 antibody with enhanced antibody-dependent cellular cytotoxicity

    Watanabe K, Shah N, Hoffmann P, et al.

    Preclinical characterization of BPC-203, an Fc-engineered anti-CD19 monoclonal antibody with selective natural killer cell engagement.

    DOI: 10.1080/19420862.[sample]
  • Cell Chemical Biology 2022

    A structure-guided platform for the discovery of selective kinase inhibitors

    Raman A, Fischer L, Becker T, et al.

    An overview of the structure-guided discovery platform underlying the BPC-101 and BPC-305 programs.

    DOI: 10.1016/j.chembiol.[sample]
  • PNAS 2022

    Antibody and antibody-drug conjugate discovery using engineered Fc libraries

    Hoffmann P, Shah N, Watanabe K, et al.

    Description of the Fc engineering library used to discover BPC-203 and to assemble the BPC-402 linker-payload.

    DOI: 10.1073/pnas.[sample]
Back to pipeline Contact about this program